483. Hereditary angioedema: pathophys, precipitants, Sx, Rx / Outpatient management of urticaria & angioedema / Clinical features and dx of mastocytosis October 24th, 2008 by reuben in allergy c1 esterase deficiency Back Top Tags: card 482. Relationship between angioedema and urticaria / Mechanisms underlying them / Ddx 484. 3 key historical points in the assessment of a rash / What is a dermatophytosis? / List of dermatophytoses / Diagnostic test of choice for dermatophytoses Responses to “483. Hereditary angioedema: pathophys, precipitants, Sx, Rx / Outpatient management of urticaria & angioedema / Clinical features and dx of mastocytosis” Please also know that while FFP has replacement C1 INH, it also has bradykinin and kalikrein which are known mediators for the swelling attack. FFP works wonderfully for some patients, but not for all. For some, because of the Kalikrein & Bradykinin, FFP could possibly exacerbate the swelling attack or lead to a rebound attack that was worse than the initial attack. C1 Inhibitory gained FDA approval on October 10th and is the preferred treatment option for HAE. Please see http://www.haea.org for up to date treatment options as well as pathophysiology and diagnosis recomendations from some of the world’s leading experts in HAE. shelby7185 at 2008-10-25 07:09 Leave a Reply Cancel reply Please post any discussion to the emupdates Reddit page.